Baird Starts Inhibitex (INHX) at Outperform; Pure Play in a HCV Sweet Spot

Baird initiates coverage on Inhibitex (NASDAQ: INHX) with a Outperform. PT $6.00.

Baird analyst says, "Many would like to find “the next VRUS”--which has rapidly moved from small- to mid-cap status as it validated the nucleoside/tide class in HCV--or anything close. The only currently investable pure-plays are INHX, which we prefer, and IDIX. INHX is still early and risky, but gains accrue earlier in this space. Our conviction would increase with four weeks of efficacy and full duration of safety for INX-189, and we’d look to add further to positions at that point."

For more ratings news on Inhibitex click here and for the rating history of Inhibitex click here.

Shares of Inhibitex closed at $3.19 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
• Canaccord Starts Galiano Gold (GAU:CN) at Buy
• Evercore ISI Starts Alvotech SA (ALVO) at Outperform